Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment

Projektinformationen

Infarnosys

ID Finanzhilfevereinbarung: 698297

DOI 10.3030/698297

Abgeschlossenes Projekt

EK-Unterschriftsdatum 7 September 2015

Startdatum 1 September 2015

Enddatum 29 Februar 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG
Hungary

Ziel

The Infarnosys project aims to launch a novel, combined biomarker diagnostic system on the market that will help clinicians and laboratories to earlier and better diagnose cardiac ischemia/reperfusion injury and prognosticate the effectiveness of the treatment. The innovative process measures MMP-2, MMP-9 and nitrotyrosin levels and tests MMP inhibitors in artery blood samples. Measuring MMP and nitrotyrosin levels enables predicting the occurrence of heart attack and helps to start the treatment much earlier. Testing MMP inhibitors on blood samples will help cardiologists to specify the treatments in a more sophisticated way.

For both men and women, coronary artery disease is the leading cause of death in Europe in spite of the fact that 80% of premature heart diseases are preventable. Earlier and better diagnosis of cardiac ischemia and reperfusion injury is crucial for reducing the number of deaths connected to cardiovascular diseases.

Our diagnostic marker combination has been tested already in a pre-clinical study and the results were published in the European Journal of Clinical Investigation. A Phase 2 project would aim a clinical trial and the Phase 1 feasibility study would prepare it by performing a market research including a market launch strategy and cost analysis, as well as it would prepare the clinical study documentation and the patenting process.

Wissenschaftliches Gebiet

• social sciences › sociology › industrial relations › automation
• social sciences › economics and business › business and management › business models
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2015

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG

• Netto-EU-Beitrag: € 50 000,00
• Adresse: HAJNOCZY UTCA 6 1 EM 1 ; 6722 Szeged ; Ungarn
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Alföld és Észak › Dél-Alföld › Csongrád
• Region: Alföld és Észak › Dél-Alföld › Csongrád
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00